Curated News
By: NewsRamp Editorial Staff
October 21, 2024
Stonegate Capital Partners Initiates Coverage on Sirona Biochem Corp, Highlighting GlycoProteMim™ Potential
Discuss on Reddit
LinkedIn
Substack
TelegramTLDR
- Sirona Biochem Corp's GlycoProteMim™ could provide an advantage in the premium skincare market.
- Sirona's goal of profitability by 2025 is driven by expected revenue from Allergan Aesthetic and commercialization of GlycoProteMim™.
- Sirona's partnerships position it to capture market share and contribute to the growth of the global skincare industry.
- Stonegate Capital Partners initiates coverage on Sirona Biochem Corp, highlighting potential standout in the skincare market.
Impact - Why it Matters
This news matters as it sheds light on the growth potential of Sirona Biochem Corp and its GlycoProteMim™ product in the skincare industry, ultimately impacting the company's future profitability and market position.
Summary
Stonegate Capital Partners has initiated coverage on Sirona Biochem Corp (TSX-V:SBM) (FSE: ZSB) (OTC: SRBCF), highlighting the potential of GlycoProteMim™ in the skincare market and the company's target of profitability by 2025.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Stonegate Capital Partners Initiates Coverage on Sirona Biochem Corp, Highlighting GlycoProteMim™ Potential
